Market Overview

UPDATE: BMO Capital Markets Initiates Abbott Laboratories at Outperform on Growth, Margin Expansion

Share:
Related ABT
Top Performing Industries For June 16, 2015
Mylan Offers Response to Abbott's Support for Perrigo Deal
FDA clears upstart Theranos' test system (Seeking Alpha)

BMO Capital Markets initiated coverage on Abbott Laboratories (NYSE: ABT) with an Outperform rating and a $36 price target.

BMO Capital Markets noted, "The new Abbott is expected to deliver 2012E sales of $21.5B (flat; up 4% ex-FX) from four distinct businesses: Nutritionals (30% of sales); Medical Products (26%); Established Pharmaceuticals (24%); and Diagnostics (20%). With leading market share positions and an extensive geographic footprint, particularly in the emerging markets (about 40% of revenue), we expect the company to benefit from a focused management team and dedicated resources, to drive mid- to high-single-digit revenue growth, expand operating margins, and deliver double-digit EPS."

Abbott Laboratories closed at $31.40 on Monday.

Latest Ratings for ABT

DateFirmActionFromTo
Jun 2015BTIG ResearchInitiates Coverage onBuy
May 2015Evercore PartnersInitiates Coverage onBuy
May 2015Evercore ISIInitiates Coverage onBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters